Medical device company JenaValve is developing the first transcatheter heart valve technology uniquely designed for the minimally invasive treatment of regurgitation and severe aortic stenosis.
JenaValve was established in 2006 to develop an innovative new transcatheter valve focused on treating both aortic regurgitation and aortic stenosis. In 2011, the first-generation transapical technology received CE-Mark for aortic stenosis and in 2013 it was the first transcatheter device in the world to receive CE-Mark for the treatment of aortic regurgitation. Since the launch of our first-generation device, the tecnology continued to innovate building upon experience through the development of the second-generation pericardial heart valve which is delivered via transfemoral access. JenaValve Technology, Inc. is currently enrolling patients in THE ALIGN AR Clinical Program focused on treating patients with severe, symptomatic aortic regurgitation and THE ALIGN AS clinical program for patients with severe, symptomatic aortic stenosis.
JenaValve commits to providing state-of-the-art technology to improve patients’ lives.
